<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563274</url>
  </required_header>
  <id_info>
    <org_study_id>T131E1</org_study_id>
    <nct_id>NCT03563274</nct_id>
  </id_info>
  <brief_title>QuiremSpheres Observational Study</brief_title>
  <acronym>Hope166</acronym>
  <official_title>Observational, Multicenter Study to Further Confirm The Efficacy and Safety of QuiremSpheres® (Holmium-166 Microspheres) Selective Internal Radiation Therapy (SIRT) in Unresectable Liver Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terumo Europe N.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Terumo Europe N.V.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to further assess treatment efficacy and safety after using
      QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or
      unresectable liver metastases suitable for SIRT and allocated to this treatment by a
      multidisciplinary tumor board.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver tumors can be of primary (Hepatocellular Carcinoma, HCC) or metastatic (mainly from
      colorectal carcinoma, CRC) origin. Both HCC and CRC are common causes of death from cancer
      worldwide. The overall incidence of HCC and CRC remains high in developing countries and is
      steadily rising in most industrialized countries. Available treatment options depend on the
      size, number, and location of tumors, on liver status, overall performance status and
      comorbidities, on patency of portal vein and presence of extrahepatic metastatic disease.
      They include surgical (liver resection, liver transplantation), systemic (e.g. chemotherapy,
      immunotherapy), ablative (thermal ablation, chemical ablation) and intra-arterial
      (chemoembolization, radioembolization) modalities. Radioembolization, also known as Selective
      Internal Radiation Therapy (SIRT) with microspheres containing a radiation-emitting isotope
      (Yttrium-90 or Holmium-166) delivers localized radiation in the vasculature around liver
      tumors with relatively limited concurrent injury to the surrounding normal/healthy tissue.
      Yttrium-90 radioembolization is currently included in several guidelines (EASLEORTC, ESMO).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Tumor response</measure>
    <time_frame>3 months</time_frame>
    <description>1. Tumor response in the liver
• Tumor response in liver for overall population and each tumor type, assessed 3 months after SIRT has been completed as per routine practice following the corresponding guidelines for each tumor type (e.g. RECIST, mRECIST, EASL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 months</time_frame>
    <description>2. Frequency and Severity of Adverse Events
• Safety will be evaluated by monitoring and recording the grade 3, 4 and 5 adverse events (AE) and all adverse device effects (ADE) occurring during and after treatment throughout follow up of patients. Severity of adverse events will be rated following the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Safety assessment will also be based on routine blood tests with an emphasis on the liver function parameters obtained at baseline, after the SIRT procedure and throughout the follow up period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression in liver and overall</measure>
    <time_frame>12 months</time_frame>
    <description>Time from SIRT procedure until progression in liver / overall progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival in liver and overall</measure>
    <time_frame>12 months</time_frame>
    <description>Time from SIRT procedure until progression in liver / overall progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>12 months</time_frame>
    <description>Time from SIRT procedure until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients downstaged to surgery, transplantation or any local ablative therapy (RFA/MWA…)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients that after the SIRT procedure underwent a surgery or transplantation</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver, Cancer of, Non-Resectable</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Selective Internal Radiation Therapy with QuiremSpheres®</intervention_name>
    <description>The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT and allocated to this treatment by a multidisciplinary tumor board.</description>
    <other_name>SIRT, Radioembolization</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with unresectable primary liver cancer or unresectable metastases in the liver.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with diagnosis of primary liver tumor or metastases in the liver from other
             primary cancers, allocated to SIRT with QuiremSpheres® as decided by a
             multidisciplinary tumor board

          -  Patient is ≥ 18 years

          -  Patient has understood and signed written informed consent to data collection in the
             study

        Exclusion Criteria:

          -  Patient's refusal

          -  Local practice guidelines prohibiting the patient to receive SIRT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dragica Paunovic, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer at Terumo Europe</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dragica Paunovic, MD</last_name>
    <phone>+32(0)16381311</phone>
    <email>Dragica.Paunovic@terumo-europe.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florence Chow</last_name>
    <phone>+32 (0)16 38 13 76</phone>
    <email>florence.chow@terumo-europe.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinischen Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Loewe, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Christian Loewe, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLV Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pieter De Bondt, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Pieter De Bondt, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Deroose, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Deroose, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf-Thorsten Hoffmann, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ralf-Thorsten Hoffmann, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Cioni, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Cioni, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marnix Lam, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Marnix Lam, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Serrano Palacio, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Serrano Palacio, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma,Holmium-166,SIRT,QuiremSpheres®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

